Oral Antibiotics Market, by Class (Beta lactam & beta lactamase inhibitors, Quinolones, Macrolide, and Others), Application (Community-Acquired Respiratory Tract Infections (CARTIS), Urinary Tract Infections (UTIS), Dental, and Others), Drug Origin (Natural, Semisynthetic, Synthetic), Spectrum Of Activity (Broad-Spectrum Antibiotic, Mid/Narrow-Spectrum Antibiotic), Drug Type (Branded And Generics): Global Opportunity Analysis and Industry Forecast, 20202027
- Published Date: 2020-11-18
- Report ID: 18331
- Pages: 329
-
Format:
The global oral antibiotics market generated $18,365.80 million in 2018, and is projected to reach $23,306.10 million by 2027, growing at a CAGR of 2.7% from 2019 to 2027.
Antibiotic is an antimicrobial substance or a compound that fights against bacterial infections and sometimes with protozoan infections, but not viral infections. These are medications that either stop bacteria from growing or kill bacteria directly, referred as bacteriostatic and bactericidal antibiotics, respectively. There are several types of antibiotics easily available at drug stores and in hospitals with a prescription or without a prescription in most of countries. Antibiotics are mostly used during transplants, dialysis, suppressed immune system, and joint replacement.
There is an increase in demand for antibiotics, owing to increased consumption in low- and middle-income countries (LMICs) and rise in prevalence of infectious diseases. In addition, development of novel approaches for new antibiotics to treat bacterial infections and large number of clinical trials further drive the market growth. However, development of antibiotic resistance, driven by misuse of antibiotics and time taken for regulatory approvals are projected to impede the market growth. On the contrary, discovery of advanced prospect molecules and novel combination therapies to treat antibiotic-resistant microbial infections are expected to offer significant profitable opportunities for the market players.
The global oral antibiotics market is segmented on the basis of class, application drug origin, spectrum of activity, application, and region. On the basis of class, the market is classified into beta lactam & beta lactamase inhibitors, quinolones, macrolides, and others. Beta lactam & beta lactamase inhibitors is further segmented into Penicillin, Cephalosporin, and others. By application, the market is divided into community- respiratory tract infections (CARTIS), urinary acquired tract infections (UTIS), dental, and others. Depending on drug origin, it is categorized into natural, semisynthetic, and synthetic. According to the spectrum of activity, it is bifurcated into broad-spectrum antibiotic and narrow-spectrum antibiotic. By drug type, it is divided into branded and generics. Region wise, the market is studied across North America, Europe, Asia-Pacific, and LAMEA.
Depending on class, the market is categorized into Beta lactam & beta lactamase inhibitors, Quinolones, Macrolide, and Others. The beta lactam & beta lactamase inhibitors segment was the highest contributor to the market in 2018. The segment is a major revenue contributor, owing to its broad-spectrum of activity A broad-spectrum antibiotic fights both Gram-negative and Gram-positive bacteria as well as effective on the multiple groups of bacterial infections.
On the basis of application, the oral antibiotics market is classified into community-acquired respiratory tract infections (CARTIs), urinary tract infections (UTIs), dental, and others. The CARTIs segment is further segmented into upper respiratory tract infections (URTI) and lower respiratory tract infections (LRTI). The dental segment is further divided into combination and monotherapies.
On the basis of drug origin, the oral antibiotics market is classified into natural, semisynthetic, and synthetic. The synthetic segment generated highest revenue in 2018, and is anticipated to maintain its dominance throughout the forecast period. This is attributed to the fact that semisynthetic oral antibiotics have improved coverage and effectiveness against a wide range of organisms.
KEY BENEFITS FOR STAKEHOLDERS
The study provides an in-depth analysis of the global oral antibiotics market size along with the current trends and future estimations to elucidate the imminent investment pockets.
It offers market analysis from 2020 to 2027, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
A comprehensive analysis on region assists to understand the regional market and facilitate the strategic business planning and determine prevailing opportunities.
The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global oral antibiotics market growth.
KEY MARKET SEGMENTS
By Class
Beta Lactam and Beta Lactamase Inhibitors
o Penicillin
Broad Spectrum Penicillin
Mid/Narrow Spectrum Penicillin
o Cephalosporin
o Others
Quinolone
Macrolide
Others
By Application
Community-respiratory tract infections (CARTIS)
o Upper Respiratory Tract Infections (URTI)
o Lower Respiratory Tract Infections (LRTI)
Urinary acquired tract infections (UTIS)
Dental
o Combination
o Monotherapies
Others
By Drug Origin
Natural
Semisynthetic
Synthetic
By Spectrum of Activity
Broad-spectrum Antibiotic
Narrow-spectrum Antibiotic
By Drug Type
Branded
Generic
By Region
North America
o U.S.
o Canada
o Mexico
Europe
o Germany
o France
o Spain
o Italy
o UK
o Russia
o Rest of Europe
Asia-Pacific
o Japan
o India
o China
o Pakistan
o Vietnam
o Rest of Asia-Pacific
LAMEA
o Brazil
o Saudi Arabia
o South Africa
o Turkey
o Rest of LAMEA
List of key players profiled in the report
Abbott Laboratories
Allergan Plc.
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline plc
Merck & Co. Inc.
Mylan N.V.
Novartis International AG (Sandoz)
Pfizer Inc.
Sanofi
Teva Pharmaceutical Industries Ltd.
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.3.1.List of key players profiled in the report
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.1.1.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Market share analysis, 2018
3.4.Porters five forces analysis
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Increase in consumption in low-and middle-income countries (LMICs)
3.5.1.2.Rise in prevalence of infectious diseases
3.5.1.3.Development of novel approaches
3.5.2.Restraints
3.5.2.1.Development of antibiotic resistance
3.5.2.2.Time consuming approvals
3.5.3.Opportunities
3.5.3.1.Discovery of advanced therapies to treat antibiotic-resistance.
3.6.Impact analysis of COVID-19 on oral antibiotics market
CHAPTER 4:ORAL ANTIBIOTICS MARKET, BY CLASS
4.1.Overview
4.1.1.Market size and forecast, by class
4.2.Beta lactam and beta lactamase inhibitors
4.2.1.Key market trends and growth opportunities
4.2.2.Market size and forecast, by type
4.2.2.1.Penicillin
4.2.2.1.1.Market size and forecast, by type
4.2.2.1.1.1.Broad-spectrum penicillin
4.2.2.1.1.2.Mid/Narrow-spectrum penicillin
4.2.2.2.Cephalosporin
4.2.2.2.1.Market size and forecast
4.2.2.2.2.Market size and forecast, by molecule
4.2.2.3.Others
4.2.2.3.1.Market size and forecast
4.2.3.Market size and forecast, by region
4.2.4.Market analysis, by country
4.3.Quinolones
4.3.1.Key market trends and growth opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country
4.4.Macrolides
4.4.1.Key market trends and growth opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country
4.5.Others
4.5.1.Key market trends and growth opportunities
4.5.2.Market size and forecast, by region
4.5.3.Market analysis, by country
CHAPTER 5:ORAL ANTIBIOTICS MARKET, BY APPLICATION
5.1.Overview
5.1.1.Market size and forecast
5.2.Community-acquired respiratory tract infections (CARTIs)
5.2.1.Market size and forecast, by type
5.2.1.1.Upper Respiratory Tract Infections (URTI)
5.2.1.1.1.Market size and forecast
5.2.1.1.2.Market size and forecast, by molecule
5.2.1.2.Lower Respiratory Tract Infections (LRTIs)
5.2.1.2.1.Market size and forecast
5.2.1.2.2.Market size and forecast, by molecule
5.2.2.Market size and forecast, by region
5.2.3.Market analysis, by country
5.3.Urinary tract infections (UTIs)
5.3.1.Market size and forecast, by molecule
5.3.2.Market size and forecast, by region
5.3.3.Market analysis, by country
5.4.Dental
5.4.1.Market size and forecast, by type
5.4.1.1.Combination
5.4.1.1.1.Market size and forecast
5.4.1.1.2.Market size and forecast, by molecule
5.4.1.2.Monotherapies
5.4.1.2.1.Market size and forecast
5.4.1.2.2.Market size and forecast, by molecule
5.4.2.Market size and forecast, by region
5.4.3.Market analysis, by country
5.5.Others
5.5.1.Market size and forecast, by region
5.5.2.Market analysis, by country
CHAPTER 6:ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN
6.1.Overview
6.1.1.Market size and forecast
6.2.Natural
6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country
6.3.Semisynthetic
6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country
6.4.Synthetic
6.4.1.Market size and forecast, by region
6.4.2.Market analysis, by country
CHAPTER 7:ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY
7.1.Overview
7.1.1.Market size and forecast
7.2.Broad-spectrum antibiotic
7.2.1.Market size and forecast, by region
7.2.2.Market analysis, by country
7.3.Mid/Narrow-spectrum antibiotic
7.3.1.Market size and forecast, by region
7.3.2.Market analysis, by country
CHAPTER 8:ORAL ANTIBIOTICS MARKET, BY DRUG TYPE
8.1.Overview
8.1.1.Market size and forecast
8.2.Branded
8.2.1.Market size and forecast, by region
8.2.2.Market analysis, by country
8.3.Generics
8.3.1.Market size and forecast, by region
8.3.2.Market analysis, by country
CHAPTER 9:ORAL ANTIBIOTICS MARKET, BY REGION
9.1.Overview
9.1.1.Market size and forecast
9.2.North America
9.2.1.Key market trends and opportunities
9.2.2.North America antibiotics market, by country
9.2.2.1.U.S. oral antibiotics market, by class
9.2.2.2.U.S. oral antibiotics market, by application
9.2.2.3.U.S. oral antibiotics market, by drug origin
9.2.2.4.U.S. oral antibiotics market, by spectrum of activity
9.2.2.5.U.S. oral antibiotics market, by Drug type
9.2.2.6.Canada oral antibiotics market, by class
9.2.2.7.Canada oral antibiotics market, by application
9.2.2.8.Canada oral antibiotics market, by drug origin
9.2.2.9.Canada oral antibiotics market, by spectrum of activity
9.2.2.10.Canada oral antibiotics market, by drug type
9.2.2.11.Mexico oral antibiotics market, by class162
9.2.2.12.Mexico oral antibiotics market, by application
9.2.2.13.Mexico oral antibiotics market, by drug origin
9.2.2.14.Mexico oral antibiotics market, by spectrum of activity
9.2.2.15.Mexico oral antibiotics market, by drug type
9.2.3.North America oral antibiotics market, by class
9.2.4.North America oral antibiotics market, by application
9.2.5.North America oral antibiotics market, by drug origin
9.2.6.North America oral antibiotics market, by spectrum of activity
9.2.7.North America antibiotics market, by drug type
9.3.Europe
9.3.1.Key market trends and opportunities
9.3.2.Europe oral antibiotics market, by country
9.3.2.1.Germany oral antibiotics market, by class
9.3.2.2.Germany oral antibiotics market, by application
9.3.2.3.Germany oral antibiotics market, by drug origin
9.3.2.4.Germany oral antibiotics market, by spectrum of activity
9.3.2.5.Germany oral antibiotics market, by Drug type
9.3.2.6.France oral antibiotics market, by class
9.3.2.7.France oral antibiotics market, by application
9.3.2.8.France oral antibiotics market, by drug origin
9.3.2.9.France oral antibiotics market, by spectrum of activity
9.3.2.10.France oral antibiotics market, by drug type
9.3.2.11.Spain oral antibiotics market, by class181
9.3.2.12.Spain oral antibiotics market, by application
9.3.2.13.Spain oral antibiotics market, by drug origin
9.3.2.14.Spain oral antibiotics market, by spectrum of activity
9.3.2.15.Spain oral antibiotics market, by drug type
9.3.2.16.Italy oral antibiotics market, by class185
9.3.2.17.Italy oral antibiotics market, by application
9.3.2.18.Italy oral antibiotics market, by drug origin
9.3.2.19.Italy oral antibiotics market, by spectrum of activity
9.3.2.20.Italy oral antibiotics market, by drug type
9.3.2.21.UK oral antibiotics market, by class
9.3.2.22.UK oral antibiotics market, by application
9.3.2.23.UK oral antibiotics market, by drug origin
9.3.2.24.UK oral antibiotics market, by spectrum of activity
9.3.2.25.UK oral antibiotics market, by drug type
9.3.2.26.Russia oral antibiotics market, by class
9.3.2.27.Russia oral antibiotics market, by application
9.3.2.28.Russia oral antibiotics market, by drug origin
9.3.2.29.Russia oral antibiotics market, by spectrum of activity
9.3.2.30.Russia oral antibiotics market, by drug type
9.3.2.31.Rest of Europe oral antibiotics market, by class
9.3.2.32.Rest of Europe oral antibiotics market, by application
9.3.2.33.Rest of Europe oral antibiotics market, by drug origin
9.3.2.34.Rest of Europe oral antibiotics market, by spectrum of activity
9.3.2.35.Rest of Europe oral antibiotics market, by drug type
9.3.3.Europe oral antibiotics market, by class
9.3.4.Europe oral antibiotics market, by application
9.3.5.Europe oral antibiotics market, by drug origin
9.3.6.Europe oral antibiotics market, by spectrum of activity
9.3.7.Europe oral antibiotics market, by drug type
9.4.Asia-Pacific
9.4.1.Key market trends and opportunities
9.4.2.Asia-Pacific oral antibiotics market, by country
9.4.2.1.Japan oral antibiotics market, by class
9.4.2.2.Japan oral antibiotics market, by application
9.4.2.3.Japan oral antibiotics market, by drug origin
9.4.2.4.Japan oral antibiotics market, by spectrum of activity
9.4.2.5.Japan oral antibiotics market, by drug type
9.4.2.6.India oral antibiotics market, by class
9.4.2.7.India oral antibiotics market, by application
9.4.2.8.India oral antibiotics market, by drug origin
9.4.2.9.India oral antibiotics market, by spectrum of activity
9.4.2.10.India oral antibiotics market, by drug type
9.4.2.11.China oral antibiotics market, by class
9.4.2.12.China oral antibiotics market, by application
9.4.2.13.China oral antibiotics market, by drug origin
9.4.2.14.China oral antibiotics market, by spectrum of activity
9.4.2.15.China oral antibiotics market, by drug type
9.4.2.16.Pakistan oral antibiotics market, by class
9.4.2.17.Pakistan oral antibiotics market, by application
9.4.2.18.Pakistan oral antibiotics market, by drug origin
9.4.2.19.Pakistan oral antibiotics market, by spectrum of activity
9.4.2.20.Pakistan oral antibiotics market, by Drug type
9.4.2.21.Vietnam oral antibiotics market, by class
9.4.2.22.Vietnam oral antibiotics market, by application
9.4.2.23.Vietnam oral antibiotics market, by drug origin
9.4.2.24.Vietnam oral antibiotics market, by spectrum of activity
9.4.2.25.Vietnam oral antibiotics market, by Drug type
9.4.2.26.Rest of Asia-Pacific oral antibiotics market, by class
9.4.2.27.Rest of Asia-Pacific oral antibiotics market, by application
9.4.2.28.Rest of Asia-Pacific oral antibiotics market, by drug origin
9.4.2.29.Rest of Asia-Pacific oral antibiotics market, by spectrum of activity
9.4.2.30.Rest of Asia-Pacific oral antibiotics market, by drug type
9.4.3.Asia-Pacific oral antibiotics market, by class
9.4.4.Asia-Pacific oral antibiotics market, by application
9.4.5.Asia-Pacific oral antibiotics market, by drug origin
9.4.6.Asia-Pacific oral antibiotics market, by spectrum of activity
9.4.7.Asia-Pacific oral antibiotics market, by drug type
9.5.LAMEA
9.5.1.Key market trends and opportunities
9.5.2.LAMEA antibiotics market, by country
9.5.2.1.Brazil oral antibiotics market, by class
9.5.2.2.Brazil oral antibiotics market, by application
9.5.2.3.Brazil oral antibiotics market, by drug origin
9.5.2.4.Brazil oral antibiotics market, by spectrum of activity
9.5.2.5.Brazil oral antibiotics market, by drug type
9.5.2.6.Saudi Arabia oral antibiotics market, by class
9.5.2.7.Saudi Arabia oral antibiotics market, by application
9.5.2.8.Saudi Arabia oral antibiotics market, by drug origin
9.5.2.9.Saudi Arabia oral antibiotics market, by spectrum of activity
9.5.2.10.Saudi Arabia oral antibiotics market, by application
9.5.2.11.South Africa oral antibiotics market, by class
9.5.2.12.South Africa oral antibiotics market, by application
9.5.2.13.South Africa oral antibiotics market, by drug origin
9.5.2.14.South Africa oral antibiotics market, by spectrum of activity
9.5.2.15.South Africa oral antibiotics market, by drug type
9.5.2.16.Turkey oral antibiotics market, by class
9.5.2.17.Turkey oral antibiotics market, by application
9.5.2.18.Turkey oral antibiotics market, by drug origin
9.5.2.19.Turkey oral antibiotics market, by spectrum of activity
9.5.2.20.Turkey oral antibiotics market, by drug type
9.5.2.21.Rest of LAMEA oral antibiotics market, by class
9.5.2.22.Rest of LAMEA oral antibiotics market, by application
9.5.2.23.Rest of LAMEA oral antibiotics market, by drug origin
9.5.2.24.Rest of LAMEA oral antibiotics market, by spectrum of activity
9.5.2.25.Rest of LAMEA oral antibiotics market, by drug type
9.5.3.LAMEA antibiotics market, by class
9.5.4.LAMEA antibiotics market, by application
9.5.5.LAMEA antibiotics market, by drug origin
9.5.6.LAMEA antibiotics market, by spectrum of activity
9.5.7.LAMEA antibiotics market, by drug type
CHAPTER 10:COMPANY PROFILES
10.1.ABBOTT LABORATORIES
10.1.1.Company overview
10.1.2.Company snapshot
10.1.3.Operating business segments
10.1.4.Product portfolio
10.1.5.Business performance
10.2.ALLERGAN PLC
10.2.1.Company overview
10.2.2.Company snapshot
10.2.3.Operating business segments
10.2.4.Product portfolio
10.2.5.Business performance
10.2.6.Key strategic moves and developments
10.3.F. HOFFMANN-LA ROCHE LTD.
10.3.1.Company overview
10.3.2.Company snapshot
10.3.3.Operating business segments
10.3.4.Product portfolio
10.3.5.Business performance
10.3.6.Key strategic moves and developments
10.4.GLAXOSMITHKLINE PLC
10.4.1.Company overview
10.4.2.Company snapshot
10.4.3.Operating business segments
10.4.4.Product portfolio
10.4.5.Business performance
10.4.6.Key strategic moves and developments
10.5.MERCK & CO., INC.
10.5.1.Company overview
10.5.2.Company snapshot
10.5.3.Operating business segments
10.5.4.Product portfolio
10.5.5.Business performance
10.5.6.Key strategic moves and developments
10.6.MYLAN N.V.
10.6.1.Company overview
10.6.2.Company snapshot
10.6.3.Operating business segments
10.6.4.Product portfolio
10.6.5.Business performance
10.6.6.Key strategic moves and developments
10.7.NOVARTIS INTERNATIONAL AG (PEAR THERAPEUTICS, INC.)
10.7.1.Company overview
10.7.2.Company snapshot
10.7.3.Operating business segments
10.7.4.Product portfolio
10.7.5.Business performance
10.7.6.Key strategic moves and developments
10.8.PFIZER INC.
10.8.1.Company overview
10.8.2.Company snapshot
10.8.3.Operating business segments
10.8.4.Operating Product
10.8.5.Business performance
10.8.6.Key strategic moves and developments
10.9.SANOFI
10.9.1.Company overview
10.9.2.Company snapshot
10.9.3.Operating business segments
10.9.4.Product portfolio
10.9.5.Business performance
10.9.6.Key strategic moves and developments
10.10.TEVA PHARMACEUTICAL INDUSTRIES LTD.
10.10.1.Company overview
10.10.2.Company snapshot
10.10.3.Operating business segments
10.10.4.Product portfolio
10.10.5.Business performance
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
